the rationale for replacement therapy of hemophilia depends on assessment of the severity of a given hemorrhagic episode followed by single , multiple , or continuous infusions of factor viii concentrates sufficient to raise the plasma ahf to the hemostatic level ( 15 - less than 50 % , depending on the severity of hemorrhage ) .
C0019069
hemophilia
C0015506
ahf